GlassScriptPhysician profile
John William Lunsford
NPI 1013916899
$12,417.48
in general payments reported to CMS, 2019-2025
50 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,424 · 2020: $1,549 · 2021: $1,831 · 2022: $1,990 · 2023: $1,876 · 2024: $1,838 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,623.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,182.15 | 2019-2025 | |
| Novo Nordisk INC | $1,558.04 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,121.08 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,011.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $872.50 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $662.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $515.24 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.59 | 2020-2025 | Jardiance |
| Amgen INC. | $382.38 | 2020-2025 | Evenity, Prolia, Otezla |
| Teva Pharmaceuticals USA, INC. | $336.39 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Novartis Pharmaceuticals Corporation | $327.28 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $302.61 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $233.28 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.63 | 2024-2025 | Caplyta |
| Allergan, INC. | $175.99 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lunsford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.